Annual Exacerbation Rates · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics probably leads to lower rate of exacerbation per patient/year WMD of compared with placebo (moderate certainty).
1 finding from 1 review
HRQoL: total score · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
1 finding from 1 review
All‐cause mortality WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in all‐cause mortality WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Serious adverse events WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in serious adverse events WMD of compared with placebo (moderate certainty).
1 finding from 1 review
Any adverse event WMD of · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
Antibiotics showed no clear difference in any adverse event WMD of compared with placebo (moderate certainty).
1 finding from 1 review
FEV1 · Adults (aged 40 or over) with COPD presenting with 1 or more exacerbations in the previous year. The 2 larger studies (Albert 2011; Sethi…
1 finding from 1 review
Quality of life at 3 months after surgery · patients undergoing cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Central retinal thickness at 3 months after surgery; · patients undergoing cataract surgery
1 finding from 1 review
Adverse effects · patients undergoing cataract surgery
1 finding from 1 review
MO at 3 months after cataract surgery, clinically symptomatic, · patients undergoing cataract surgery
NSAIDS may leads to lower MO at 3 months after cataract surgery; clinically symptomatic compared with steroids (low certainty).
1 finding from 1 review
Mean postoperative best‐corrected visual acuity · patients undergoing cataract surgery
1 finding from 1 review
Poor vision due to MO at 3 months after surgery · patients undergoing cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Poor vision due to MO at 12 months after surgery · patients undergoing cataract surgery
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Induction of remission (CDAI < or =150 with or without decrease of at least 60 points) · patients with Induction of remission or response in Crohn's disease
Delayed‐release mesalamine (3 ‐ 4.5 g/day) showed no clear difference in induction of remission (CDAI < or =150 with or without decrease of… compared with corticosteroids (moderate certainty).
5 findings from 1 review
RR 1.04 [0.79, 1.36]
3 studies · 178 participants
Moderate
RR 0.95 [0.49, 1.85]
1 study · 50 participants
Low
RR 1 [0.61, 1.64]
1 study · 50 participants
Moderate
Show 2 more findings
CDAI <150 at 24 weeks · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission (CDAI <150) compared with corticosteroids (moderate certainty).
1 finding from 1 review
Remission · patients with Induction of remission or response in Crohn's disease
Sulfasalazine probably leads to lower induction of remission compared with sulfasalazine and corticosteroids (moderate certainty).
1 finding from 1 review
Clinical remission · Patients with active Crohn's disease
Budesonide 9 mg probably leads to lower induction of clinical remission (CDAI < 150) ‐ 8 weeks compared with conventional steroids (moderate certainty).
1 finding from 1 review
Withdrawals due to adverse events · Patients with active Crohn's disease
Budesonide 9 mg showed no clear difference in withdrawal due to adverse events compared with conventional steroids (low certainty).
1 finding from 1 review
Withdrawal due to disease worsening · Patients with active Crohn's disease
It is very uncertain whether budesonide 9 mg changes withdrawal due to disease worsening compared with conventional steroids (very low certainty).
1 finding from 1 review
Clinical improvement · patients with induction of remission in ulcerative colitis
It is very uncertain whether UFH changes clinical improvement compared with corticosteroids (very low certainty).
1 finding from 1 review